64 related articles for article (PubMed ID: 23207506)
1. ART regimen protects children from malaria.
BMJ; 2012 Dec; 345():e8214. PubMed ID: 23207506
[No Abstract] [Full Text] [Related]
2. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
3. Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Redmond AM; Skinner-Adams T; Andrews KT; Gardiner DL; Ray J; Kelly M; McCarthy JS
AIDS; 2007 Mar; 21(6):763-5. PubMed ID: 17413699
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
[TBL] [Abstract][Full Text] [Related]
5. Initial therapy for HIV: can less be more?
Sax PE
Lancet Infect Dis; 2014 Jul; 14(7):535-7. PubMed ID: 24783987
[No Abstract] [Full Text] [Related]
6. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
Espiau M; Soler-Palacín P; Borrull A; Figueras C
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
[No Abstract] [Full Text] [Related]
7. Barriers to simplified HIV treatment in low-resource settings.
Moreira J
Lancet Infect Dis; 2014 Dec; 14(12):1178-9. PubMed ID: 25455981
[No Abstract] [Full Text] [Related]
8. Initial treatment of HIV-1 infection.
Schulz TR; Street AC
N Engl J Med; 2008 Aug; 359(9):970; author reply 971. PubMed ID: 18753656
[No Abstract] [Full Text] [Related]
9. Initial treatment for HIV infection--an embarrassment of riches.
Hirschel B; Calmy A
N Engl J Med; 2008 May; 358(20):2170-2. PubMed ID: 18480210
[No Abstract] [Full Text] [Related]
10. [Not Available].
Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():1. PubMed ID: 25542867
[No Abstract] [Full Text] [Related]
11. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
13. [Lopinavir/ritonavir in human immunodeficiency virus-infected women].
Téllez MJ
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():22-5. PubMed ID: 25542872
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
15. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
[No Abstract] [Full Text] [Related]
16. Can delavirdine substitute for ritonavir?
TreatmentUpdate; 2001; 13(7):8. PubMed ID: 11794866
[No Abstract] [Full Text] [Related]
17. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir. (Kaletra).
Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
[No Abstract] [Full Text] [Related]
19. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
20. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
